Kintor Pharmaceutical Ltd.

“In the following 10 to 20 years, the next R&D peak in small molecules lies in protein degradation; protein degraders will have a market worth at least $100bn,” Liqiang Fu, co-founder and chief te

Chinese developers of COVID-19 antivirals and vaccines are diverging on whether to stay in the game, underscored by mixed first-half progress against the mutating SARS-CoV-2 virus. The Omicron subvari

A decade into their quest to conduct successful Phase III clinical trials in the US, Chinese developers of innovative drugs seemed to lose steam in 2022 - but are still clinging to new hope over the u

A decade into their quest to conduct successful Phase III clinical trials in the US, Chinese developers of innovative drugs seemed to lose steam in 2022 – but are still clinging to new hope over the u